Fortune 500 list released! 2 Chinese pharmaceutical companies shortlisted

[industry trends of pharmaceutical Station] on July 22, fortune Chinese and the world released the 2019 Fortune Global 500 ranking simultaneously According to incomplete statistics, there are 11 pharmaceutical enterprises on the list, including Pfizer, Roche and other well-known foreign pharmaceutical enterprises, and 2 domestic pharmaceutical enterprises, including China Pharmaceutical Group and China Huarun Co., Ltd According to the specific ranking, kantle (38), China Resources (80), Johnson & Johnson (109), Roche (163), China Pharmaceutical Group (169), Pfizer (198), GlaxoSmithKline (296), Novartis (201), MSD (285), Sanofi (288 blocks), Alberto (381), Phoenix medical company (412) Kantor, ranked 38 by Kantor, has an operating revenue of US $136809 million and a profit of US $256 million According to public information, kantle is a leading enterprise in the field of medical services, serving more than 60000 medical service institutions and 50000 customers in North America every day, accounting for one third of all drug distribution, laboratories and medical supplies in the United States and Puerto Rico China Resources ranks 80th in the 2019 world top 500 list The pharmaceutical sector of China Resources Company is mainly China Resources pharmaceutical, with annual revenue of more than HK $180 billion Johnson & Johnson ranked 109 with operating revenue of $81581 million and profit of $15297 million It is reported that the recent growth of Johnson & Johnson, a multi billion dollar pharmaceutical company, is mainly driven by the pharmaceutical sector Roche ranked 163 with operating revenue of USD 60846.20 million and profit of USD 10738.10 million According to the public information, Roche Group is the world leader in the field of pharmaceutical and diagnosis Based on R & D, the company aims to provide targeted treatment programs for each patient through personalized medical treatment China Pharmaceutical Group ranked 169, with operating revenue of US $59980.200 million and profit of US $884.4 million According to the data, China Pharmaceutical Group is a large-scale biomedical R & D and production enterprise in China, which undertakes more than 80% of the production tasks of vaccines for national immunization program Pfizer ranked 198 with operating revenue of USD 53647 million and profit of USD 11153 million According to public information, Pfizer is a large-scale R & D-based biopharmaceutical company in the world In the 2017 Fortune 500, it ranked 173; in 2016, it ranked 186 GlaxoSmithKline ranked 296, with operating revenue of US $41108.50 million and profit of US $4832.30 million GlaxoSmithKline is a R & D-based pharmaceutical and health products company with products throughout the global market Novartis ranked 201, with operating revenue of US $53166 million and profit of US $12611 million Novartis group has a diversified business portfolio covering innovative drugs, eye care, consumer care, vaccines and diagnostics, and is a world leader in all areas MSD ranked 285, with operating revenue of US $42294 million and profit of US $6220 million According to the ranking information of previous years, MSD ranked 69th in the 2017 Fortune 500 list, and 276 in the 2018 Fortune 500 list Sanofi ranked 288, with operating revenue of US $42104.90 million and profit of US $5081.80 million Sanofi's main business covers pharmaceutical, human vaccine and animal health Ebway ranked 381 with revenue of $32753 million and profit of $5687 million This is a research-based American biopharmaceutical company Phoenix Contact Pharmaceutical Co., Ltd ranked 412, with operating revenue of US $30296 million and profit of US $174.5 million Phoenix Contact Pharmaceutical Co., Ltd is a German giant pharmaceutical company and the second largest pharmaceutical company in Europe In the 2018 Fortune Global 500 list, Phoenix medical company of Germany ranked 417.